Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Merck & Co Inc

Merck Lays Out Keytruda Data In Post Surgery Early-Stage Lung Cancer Setting

Merck & Co Inc (NYSE: MRK) announced results from the Phase 3 KEYNOTE-091 trial evaluating Keytruda compared to placebo for adjuvant treatment of non-small cell lung cancer (NSCLC).

Benzinga · Mar 18, 2022

Merck-AstraZeneca Stop Keytruda/Lynparza Combo Trial In Prostate Cancer Patients

Merck & Co Inc (NYSE: MRK) will stop the Phase 3 KEYLYNK-010 trial investigating Keytruda combined with Lynparza for metastatic castration-resistant prostate cancer (mCRPC).

Benzinga · Mar 15, 2022

Merck's Keytruda Shows Improved Metastasis-Free Survival In Melanoma Patients

Merck & Co Inc (NYSE: MRK) announced data from Phase 3 KEYNOTE-716 trial of Keytruda (pembrolizumab) as adjuvant treatment for patients with resected stage IIB and IIC melanoma.

Benzinga · Mar 7, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

See Why Did FDA Update Merck's COVID-19 Pill Emergency Use Authorization

The FDA has revised the Emergency Use Authorization (EUA) for Merck & Co Inc's (NYSE: MRK) COVID-19 pill mo

Benzinga · Feb 18, 2022

South Africa Authorizes Merck's COVID-19 Antiviral Pill, But Government Not Buying: Reuters

South Africa's government said it was not planning to buy Merck & Co Inc's (NYSE: MRK) COVID-19 treatment pill molnupiravir for cost reasons, despite the drug gaining approval in the country.

Benzinga · Feb 17, 2022

Merck Inks Oncology, Neurology Drug Discovery Pact With British Biotech, Curve Therapeutics

Privately-held Curve Therapeutics has inked a contract with Merck & Co Inc (NYSE: MRK) to discover and validate modulators of up to five therapeutic targets using its Microcycle technology, initially for oncology and neurology indications.

Benzinga · Feb 16, 2022

Merck Clocked $950M Sales In Q4 From COVID-19 Treatment, Issues FY22 Sales

Merck & Co Inc's (NYSE: MRK) Q4 sales re

Benzinga · Feb 3, 2022

Read news from The Economist, FT, and more,
with one subscription

Merck's COVID-19 Pill works Against Omicron, Lab Studies Show

Merck & Co Inc (NYSE: MRK) and its partner Ridgeback Biotherapeutics said six lab studies showed their investigational oral COVID-19 drug molnupiravir was

Benzinga · Jan 28, 2022

Cue Pharma Posts Two Responses From CUE-101 Combo In Head & Neck Cancer

Early data from a trial evaluating Cue Biopharma Inc's (NASDAQ: CUE) CUE-101 combined with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) demonstrated that

Benzinga · Jan 27, 2022

Britain To Test Merck - Ridgeback Biotherapeutics' COVID-19 Antiviral Pill In Hospitalized Patients

British scientists will start testing Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics' COVID-19 antiviral pill molnupiravir as a possible treatment for patients hospitalized with COVID-19,

Benzinga · Jan 24, 2022

Merck Scores Win In Insurance Battle Over Cyberattack - Bloomberg Report

Bloomberg reported that Merck & Co Inc (NYSE: MRK) has won a long-running legal battle to force its insurer to cover the costs of damages caused by the NotPetya' ransomware' attacks.

Benzinga · Jan 21, 2022

Merck's Keytruda Manages To Cross The Finish Line In Liver Cancer Confirmatory Trial

Merck & Co Inc (NYSE: MRK) has

Benzinga · Jan 19, 2022

Coverage From

Benzinga

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Places

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.